• Innovative Company SHIONOGI

What's New

  • Show All
2017/01/12
SHIONOGI ANNOUNCES POSITIVE TOP-LINE RESULTS FOR CEFIDEROCOL PIVOTAL cUTI CLINICAL TRIAL
2017/01/10
Notice Regarding Completion of Cancellation of Treasury Shares
2016/12/21
Shionogi Establishes Japanese Subsidiaries
2016/12/19
“Cymbalta® Capsules 20 mg•30 mg” (Serotonin-noradrenaline reuptake inhibitor) Approved for an additional indication of pain associated with osteoarthritis
2016/12/19
SHIONOGI AND PURDUE PHARMA ESTABLISH ALLIANCE FOR JOINT U.S. COMMERCIALIZATION OF NALDEMEDINE
2016/12/08
Notice of Completion of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2016/12/05
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2016/12/01
Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released - Oral Presentation Presented at APCCMI -
2016/11/28
The Decision of Patent Revocation and Patent Infringement Actions against MSD in United Kingdom Concerning HIV Integrase Inhibitors
2016/11/24
License agreement with Tokushima University on the novel type A2 Botulinum toxin candidate for the post-stroke spasticity treatment
2016/11/08
Audio webcasting: First Half of FY2016 Financial Results and Updates to Shionogi Growth Strategy (SGS2020)
2016/11/08
Notification of Results of Share Repurchase Through the Off-auction Own Share Repurchase Transaction (ToSTNeT-3) System
2016/11/07
Notification Regarding Share Repurchase Through the Off-auction Own Share Repurchase Transaction (ToSTNeT-3) System